T he evidence that depression is a risk factor for the development and progression of CHD has strengthened over the past several years. The accompanying article by Frasure-Smith and Lespérance provides an update to this literature (1). Earlier papers proposed several candidate mechanisms to explain these effects, including behavioural factors such as nonadherence to medical treatment and physiological factors such as cardiac autonomic dysregulation. Additional physiological mechanisms have recently been proposed, including blood clotting factors, inflammatory processes, shared genetic factors, alterations in glucose metabolism, and others. This paper selectively reviews recent research on mechanisms that may explain the effects of depression on CHD outcomes. It emphasizes some of the most important findings published since 2002, when we last reviewed this literature (2). Objective: Both behavioural and physiological factors have been proposed as mechanisms that may explain the negative effect of depression on coronary heart disease (CHD). Our aim is to review some of the most important findings since our prior review.
Mechanisms as Mediators
A mechanism, in the sense discussed in this paper, is a variable on a causal pathway linking depression to cardiac outcomes such as acute MI or sudden cardiac death. Most candidate mechanisms are factors that have either been found to predict these outcomes or are known to play an etiologic role in them.
To become established as a mechanism, a factor that is already known to predict or contribute to cardiac outcomes must first be shown to correlate with depression. It must then be shown to mediate the statistical relation between depression and the cardiac outcome in question. A convincing test of a mediation hypothesis requires that the onset of depression must have preceded the proposed mechanism and that the mechanistic factor (for example, an elevation in the plasma level of a proinflammatory cytokine) must have in turn preceded the cardiac outcome. Partial mediation is demonstrated when adding a mechanistic variable to a statistical model diminishes the predictive association between depression and a cardiac outcome but does not eliminate it altogether. Partial mediation implies that the variable in question is probably not the only mechanism; other variables (which may or may not have been measured) probably also play a role.
Full mediation would be demonstrated if adding the mechanistic variable to the predictive model completely abolished the relation between depression and the cardiac outcome, but full mediation is almost never reported. Because virtually all the mechanisms under study are only partial mediators, it is important to investigate the interrelations among them.
However, there has been little of this type of integrative research so far.
In addition, most of the mechanistic work in this area has been based on observational research. Only a few clinical trials have been designed to show whether treating depression improves any of the mechanistic factors discussed in this paper (see 3, 4) . This type of research can be challenging because the mechanistic effects of change in depression tend to be confounded with the particular treatments used to produce this change. For example, treatment with sertraline might decrease platelet activation via change in depression or via direct effects on platelet serotonin receptors. Despite such difficulties, clinical trials will inevitably play an important role in mechanistic research on depression in CHD.
Major Cardiac Risk Factors
Depression is associated with several other CRFs including smoking, sedentary lifestyle, obesity, diabetes, and hypertension (2, 5, 6) , but many studies have shown that depression also has independent effects on cardiac outcomes after adjusting for CRFs. Brummett and others recently studied depression in relation to self-reported smoking and exercise in 1250 patients admitted for coronary angiography (7) . Smoking, sedentary behaviour, and depression each independently predicted mortality. In addition, smoking and sedentary behaviour also partially mediated the effect of depression on mortality.
Egede and others used data from 10 025 participants in the National Health and Nutrition Examination Survey I Epidemiological Follow-up Study to investigate the effects of depression and diabetes on all-cause and CHD mortality (8) . The effects on 8-year mortality of depression (HR 1.20 for all-cause and HR 1.29 for CHD mortality) were smaller than the effects of diabetes (HR 1.88 for all-cause and HR 2.29 for CHD mortality). The combination of depression and diabetes increased the risk (HR 2.50 for all-cause and HR 2.43 for CHD mortality), suggesting that diabetes does not completely explain the association between depression and CHD.
The INTERHEART investigators studied 15 152 patients with a first MI and 14 842 age-matched control subjects to evaluate traditional and emerging CRFs (9) ; complete data on behavioural and psychosocial CRFs were available for 11 119 cases and 13 648 control subjects. Depression was significantly associated with acute MI after adjusting age, sex, and other CRFs (OR 1.55; 95%CI, 1.42 to 1.69). The strength of this association did not differ by sex, but it did depend on the frequency of perceived stress at home or work, and it was highest among individuals who reported experiencing permanent (constant) stress at home or work (OR 2.40; 95%CI, 1.83 to 3.15) (9). 
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Coronary Disease Severity
Disease severity is usually discussed as a potential confounder of the relation between depression and cardiac outcomes rather than as a candidate mechanism. If the sickest patients in a particular population (for example, the ones with the largest MIs) tend to be the ones who develop depression, then the relative severity of their heart disease might explain both their depression and their high risk of adverse cardiac outcomes. However, if patients with depression tend to be the ones who develop the most severe disease (for example, if patients with depression tend to have more severe MIs than do patients without depression), then it might be better to conceptualize disease severity as a candidate mechanism rather than as a confounder.
There is little evidence to support either possibility, at least in terms of standard physiological indicators of the severity of heart disease, such as the extent of coronary atherosclerosis, the size of the infarct in post-MI patients, or the degree to which their left ventricular ejection fraction has been reduced. In contrast, there is considerable evidence of a strong association between depression and the severity of functional impairment in heart disease, as well as in other chronic medical illnesses (for example, 10, 11) . The relation appears to be a reciprocal one, such that functional impairment may contribute to the onset or persistence of depression, and depression may worsen the functional effects of heart disease. If functional impairment is expressed as a decrement in physical activity or self-care, this could accelerate progression of CHD. However, there has been little research on functional impairment as a candidate mediator of the relation between depression and cardiac outcomes.
Adherence to Treatment Recommendations
Depression decreases adherence to medication regimens, lifestyle risk factor interventions, and cardiac rehabilitation (2).
In the Heart and Soul Study (12) , 940 outpatients with stable CHD were assessed for self-reported medication adherence. Depression was assessed by the computerized Diagnostic Interview Schedule. The nonadherence rates were 5% for patients without depression, 7% for those with mild depression, and 14% for those with severe depression. An earlier study using medication monitors to obtain objective data on adherence (13) found that CHD patients with depression were less adherent to low-dose aspirin and that poor concentration was the symptom most predictive of nonadherence (14).
Treatment seeking may be related to adherence: both involve behavioural responses to symptoms or medical advice. Early presentation to an emergency facility is associated with reduced myocardial damage and mortality. Bunde and Martin interviewed patients approximately 9 days after an acute MI and assessed whether depression had been present prior to the MI (15) . Independently of several potential confounders, depression was associated with delay in seeking treatment.
Thus depression may affect cardiac outcomes via the behavioural mechanisms of delay in seeking treatment and nonadherence to secondary prevention. Additional studies are needed to determine whether depression has more pronounced effects on some facets of secondary prevention than on others and whether intervention to improve depressive symptoms results in improved adherence.
Altered Cardiac Autonomic Tone
The autonomic nervous system is dysregulated in CHD patients with depression (16) . Decreased parasympathetic or increased sympathetic activity may promote myocardial ischemia, ventricular tachycardia, ventricular fibrillation, and sudden cardiac death (17) (18) (19) .
HRV refers to beat-to-beat changes in heart rate as the heart responds to internal and external stimuli; it is a noninvasive measure of cardiac autonomic nervous system responsivity (20) . Low HRV indicates excessive sympathetic or inadequate parasympathetic heart rate modulation, and is a powerful, independent predictor of mortality in CHD (21) (22) (23) (24) . HRV is lower in CHD patients with depression than in CHD patients without depression (25) (26) (27) (28) (29) (30) . One study, however, found no HRV difference (31) despite higher urinary cortisol in CHD patients with depression, suggesting increased hypothalamic-pituitary-adrenal axis activity (32) .
Other indications of autonomic nervous system dysfunction in CHD patients with depression include elevated heart rate (25, 33) , increased heart rate response to orthostatic challenge (33), abnormal heart rate response to premature ventricular contractions (34) , and increased QT interval variability, indicating abnormal ventricular repolarization (35) . All these factors are strong predictors of mortality in cardiac patients.
We recently investigated whether the relation between depression and mortality is mediated by low HRV in 311 patients with depression and 367 patients without depression with a recent acute MI (36) . VLF power is an HRV index that reflects vagal modulation of heart rate. VLF was lower in the patients with depression, and they were found to be at higher risk for all-cause mortality (adjusted HR 2.8; 95% CI, 1.4 to 5.4). Addition of VLF to the model reduced this HR to 2.1 (95%CI, 1.1 to 4.2) and accounted for approximately 30% of the mortality risk of depression. Thus, low HRV partly mediates the effect of depression on post-MI survival. As noted previously, partial mediation implies that other mechanisms, possibly including other manifestations of autonomic nervous system dysfunction, also participate in the relation between depression and cardiac mortality.
Little is known about whether treating depression improves HRV. In one of the only studies to date designed to address this question, we used cognitive-behavioural therapy to treat 37 depression patients with stable CAD. Following treatment, average 24-hour heart rate and daytime rMSSD (a time-domain HRV index that primarily reflects parasympathetic activity) improved significantly in the patients with severe depression but remained unchanged in the patients with mild depression, as well as in 26 untreated control patients without depression. None of the other HRV indices showed significant improvement (3).
Prothrombotic Factors and Endothelial Dysfunction
Research on blood clotting mechanisms has produced an interesting conundrum. Imbalances between prothrombotic and antithrombotic pathways contribute to ACS (37), and as discussed below, depression has been linked to prothrombotic factors in CHD. However, depression is a stronger predictor of lethal arrhythmias and cardiac death than of nonfatal MI (38) . Prothrombotic factors can contribute to myocardial ischemia, and this in turn can precipitate lethal ventricular arrhythmias in some patients (39, 40) . It is also possible that depression contributes both to myocardial ischemia and to other factors that promote lethal ventricular arrhythmias in ischemic myocardium.
Serebruany and others combined baseline plasma samples from several trials that employed similar procedures and assays (41) . The samples came from patients with acute MI in the ASSENT-2 trial, from patients with unstable angina in the PRONTO trial, from patients with major depression and ACS from the SADHART trial, and from 50 healthy control subjects. The samples were drawn before thrombolytics, antidepressants, or any other interventions were initiated. Compared with the other patients, the ACS patients with depression from the SADHART trial had the highest levels of platelet factor-4, â-thromboglobulin, platelet-endothelial cell adhesion molecule-1, vascular cell adhesion molecule-1, and thromboxane. Because the ASSENT-2 and PRONTO patients were not assessed for depression, some of them might have been suffering from depression. If so, the effects of depression on platelets and endothelial function may be even stronger than the findings suggest.
In a recent review, von Känel found that most studies had not reported increased platelet aggregability in subjects with depression (42). However, several studies employing flow cytometry detected subtle indications of increased platelet activation in depression. The effects were stronger in patients with CAD than in those without CAD. Most of the studies were based on small samples and were heterogeneous as to subject characteristics and measures of depression. von Känel concluded that there was enough evidence to warrant larger, better controlled, prospectively designed studies of platelet activation as a candidate mechanism.
There is also growing interest in endothelial dysfunction as a potential link between depression and cardiac events (43, 44) . Sherwood and others measured brachial flow-mediated dilation in 143 CHD patients (45) . Flow-mediated dilation was attenuated in the 33% of patients who scored 10 or higher on the BDI, compared with those who scored below 10, suggesting that depression is associated with endothelial dysfunction in these patients.
Inflammatory Processes
Our previous review noted emerging evidence that depression may be associated with inflammatory processes in CAD (2), but little was known at the time about whether depression actually promotes inflammatory processes. Some studies showed elevated circulating levels of IL-6, CRP, and TNF-á, but potential confounders such as smoking, medications, and infectious illness had not been controlled. There had also been little research on the pathways through which depression might promote or maintain inflammatory activity. Since then, much of the new research on physiological mechanisms linking depression to CHD morbidity and mortality has focused on inflammatory processes.
Medically Well Populations
Several recent studies have examined associations between depression and inflammatory markers in healthy adults. For example, Miller and others reported that otherwise healthy subjects with depression had higher levels of CRP and IL-6 than the control subjects (46). Miller and others also reported that, after adjusting for demographic factors, smoking, adiposity, and contraceptives, BDI scores were independently associated with IL-6 and TNF-á but not IL-1â (47).
Danner and others studied the association between a history of major depression and CRP in 6149 participants in the Third National Health and Nutrition Examination Survey (48) . There were significant associations in men between CRP and the time since the last depressive episode. The adjusted ORs for men ranged from 1.51 for episodes occurring more than 6 months ago to 3.98 for recent episodes; there was no association in women.
nonfatal MI, or cardiac death with 670 age-matched control subjects (49 
Patients With Coronary Heart Disease
Recent studies have also examined relations between depression and inflammatory markers in CHD. Lespérance and others administered the Structured Clinical Interview for DSM-IV to 481 patients 2 months after hospitalization for ACS (50) . Approximately 7% met the DSM-IV criteria for a current major depressive episode. Compared with the patients without depression, those with major depression had significantly higher levels of soluble intercellular adhesion molecule-1 after adjustment for sex, current smoking, and metabolic syndrome. The effect was attenuated when antidepressant use was added to the model. Depression was also studied in relation to IL-6 and CRP. Neither association was significant, but statin use moderated the relation between depression and CRP. Depression was unrelated to CRP among patients who were taking statins but associated with substantially higher CRP levels among those who were not on statins.
Miller and others studied 65 medically stable outpatients with a history of ACS (51) . DSM-IV diagnoses were derived from the Depression Interview and Structured Hamilton, and the highly correlated BDI and Hamilton Depression Rating Scale scores were combined into a single depression severity index. Several inflammatory markers were measured along with antibodies against 3 viruses that may accelerate CAD progression: cytomegalovirus, herpes simplex, and Epstein-Barr virus. The severity of depression correlated with higher CRP (r = 0.27) but not with IL-6 or TNF-á. Patients scoring in the highest tertile of depression severity had higher CRP than other patients. Also, 100% of those in the highest depression tertile were seropositive to all 3 viruses, compared with only 55% in the middle tertile and 43% in the lowest tertile (P = 0.001). However, there was no relation between depression diagnosis and any of the inflammatory markers or viruses. None of the observed relations were altered by adjustment for the severity or treatment of CHD.
The Lespérance and others (50) and Miller and others (51) studies were based on post-ACS patients. Schins and others (52) recently focused more narrowly on 57 post-MI patients who scored >10 on the BDI and who met the DSM-IV criteria for a major or minor depressive episode, along with 46 post-MI patients without depression matched for age, sex, and time elapsed between the MI and study enrolment. They found no differences between patients with and without depression on any of the inflammatory markers, including cytokines (IL-6 and TNF-á), soluble cytokine receptors (sTNF-R1, sTNF-R2, and sIL-6R), inflammation-sensitive proteins (CRP and haptoglobin), and a marker of cellular immune system activation (neopterin). They noted that several markers were elevated in both groups, that many participants were taking statins, and that both of these factors possibly influenced the results. Inadequate statistical power in this relatively small study may also explain the absence of a link between depression and inflammation.
Research on inflammatory processes is expected to be one of the most active areas of mechanistic research on depression in CHD over the coming decade. One of the most important questions for further investigation is whether the proinflammatory effects of depression are mediated by other CRFs, particularly adiposity (46).
Omega-3 Polyunsaturated Fatty Acids
PUFAs are key constituents of many different types of cells. Most PUFAs are either of the omega-3 or omega-6 series, which contain an unsaturated bond at the third (omega-3) or sixth (omega-6) carbon from the methyl end of the fatty acid. Certain fishes, grains, and nuts are high in omega-3, whereas vegetable oils tend to be higher in omega-6 PUFAs.
Omega-3 PUFAs have been shown to decrease circulating markers of inflammatory processes and endothelial dysfunction (53) (54) (55) . Epidemiologic studies have found an inverse relation between intake of fish high in omega-3 PUFAs and CHD mortality, especially sudden cardiac death (56) . Other studies have found that low plasma levels of DHA and EPA, 2 forms of omega-3 found principally in fatty fish, increase the risk of cardiovascular mortality, especially sudden cardiac death (57, 58) .
Epidemiologic studies have also found strong, inverse relations between DHA-and EPA-rich diets or plasma levels of these omega-3 PUFAs and the prevalence of major depression, postpartum depression, and suicidal ideation (59) (60) (61) .
There is some evidence that increasing omega-3 intake may improve depressed mood and prevent relapse in bipolar disorder and unipolar major depression (62) (63) (64) .
There is also evidence that CHD patients with depression have lower plasma levels of omega-3 than do patients without depression. Frasure-Smith and colleagues compared 54 patients with a recent ACS and current major depression with 54 age and sex-matched ACS patients without depression (65) . The patients with depression had lower plasma concentrations of total omega-3 and DHA, as well as a greater imbalance between omega-3 and omega-6 PUFAs, than did the patients without depression. If depression contributes to a further lowering of omega-3 levels, either as a result of dietary, genetic, or other influences, patients with depression may be at higher risk for CHD mortality, and especially for sudden cardiac death.
Genetic Determinants
Depression is heritable (66, 67) , as are other CRFs (68, 69) and possibly ischemic heart disease itself (70, 71) . Recent studies have begun to investigate whether shared genetic factors may help to explain the relation between depression and CHD. A study of 2731 complete male-male twin pairs (mean age 41.9 years, SD 2.7) from the Vietnam Era Twin Registry (72) showed that common genetic risk factors may indeed underlie this relation. There were significant genetic correlations between depression, hypertension (r = 0.19), and CHD (r = 0.42). A statistical model showed that CHD shares at least as much genetic variance with depression as it does with hypertension.
These findings raise the possibility that depression and CHD may be different phenotypic expressions of the same genetic substrates (73) As recently discussed by de Geus, however, evidence of genetic pleiotropy does not eliminate other causal possibilities, including pathways in which certain genes may cause depression and depression in turn causes or complicates CHD (74) . For example, Nakatani and others studied the S allele of the serotonin transporter gene-linked polymorphic region (5-HTTLPR) in 2509 post-MI patients (75) . Depression was significantly more common among patients with (48%) than without (35%) the S allele. The S allele predicted an increased risk of cardiac events (HR 1.69), but its effect was reduced to nonsignificance by adjustment for depressive symptoms. This suggests the possibility that depression may mediate the effect of this polymorphism on cardiac outcomes.
There is growing interest in the role that shared genetic factors may play in the relations between depression and some of the other physiological mechanisms discussed in this review. Genes involved in inflammation and serotonin pathways are particularly good candidates (76) .
Conclusion
Research on candidate physiological mechanisms linking depression to CHD has expanded rapidly in the past few years, and research on shared genetic factors has emerged as a promising new line of investigation. There have been some important new studies of candidate behavioural mechanisms, but research in this area lags far behind work on physiological factors. We know little about the interrelations among any of these candidates, and relations between behavioural and physiological factors are an especially important area for further investigation. We also know little about the effects of pharmacologic and psychotherapeutic treatments for depression on any of these candidate mechanisms. For all these reasons, mechanistic studies of the connection between depression and CHD will almost certainly be one of the most active areas of research in biobehavioural medicine during the remaining years of this decade.
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Résumé : Maladie coronarienne et dépression : une revue de la récente recherche mécaniste
Objectif : Des facteurs comportementaux et physiologiques ont été proposés comme mécanismes qui peuvent expliquer l'effet nuisible de la dépression sur la maladie coronarienne (MC). Notre but est d'examiner certains des résultats les plus importants depuis notre revue précédente.
Méthode : Nous avons cherché dans MEDLINE, PsycINFO et d'autres sources des études récentes de mécanismes candidats, en mettant l'accent sur les publications parues depuis 2002.
Résultats :
Les pistes physiologiques ont reçu beaucoup plus d'attention que les pistes comportementales dans la nouvelle documentation. Les études récentes ont identifié des déterminants génétiques partagés, l'inflammation, la coagulation sanguine et les mécanismes vasculaires comme étant des mécanismes explicatifs plausibles.
Conclusions :
La future recherche devrait porter sur les relations entre les mécanismes comportementaux et physiologiques ainsi que sur les effets des traitements pharmacologiques et psychothérapeutiques de la dépression sur les mécanismes candidats.
